BLU-808
Phase 2Small molecule
BLU-808 is one of 3 small molecule programs targeting Chronic Inducible Urticaria. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Chronic Inducible Urticaria
#DrugCompanyPhaseTrials
1Rhapsido
NovartisPhase 3
Barzolvolimab
CCelldex Therapeutics
Phase 3
BLU-808
BBlueprint Medicines
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Allergic Rhinoconjunctivitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BLU-808. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBlueprint Medicines